IC
IOVA icon

Ikarian Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Ikarian Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-196,000
Closed -$3.74M – 206
2021
Q4 		$3.74M Hold
196,000
– – 0.56% 41
2021
Q3 		$4.83M Sell
196,000
-4,000
-2% -$94.3K 0.34% 69
2021
Q2 		$5.2M Hold
200,000
– – 0.42% 65
2021
Q1 		$6.33M Buy
+200,000
New +$8.29M 0.21% 106

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Ikarian Capital's IOVA Position: Q1 2022 in Review

Ikarian Capital sold out of Iovance Biotherapeutics (IOVA) in Q1 2022, closing a stake of 172,521 shares — an estimated $3.29M sold.

Ikarian Capital first reported a position in IOVA in Q2 2021 and held it in 3 quarters. The position peaked at $4.55M in Q2 2021. 249 funds tracked by Wall St. Rank hold IOVA as of Q1 2022.

  • Ikarian Capital reported no remaining Iovance Biotherapeutics position as of Q1 2022 after selling out during the quarter.
  • Ikarian Capital sold 172,521 Iovance Biotherapeutics shares in Q1 2022, an estimated $3.29M.
  • Ikarian Capital first reported a position in Iovance Biotherapeutics in Q2 2021 and held it in 3 quarters.
  • Ikarian Capital's Iovance Biotherapeutics position peaked at $4.55M in Q2 2021.
  • 249 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2022.

Based on Ikarian Capital's 13F filing for Q1 2022, filed 13 May 2022.